Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, with dissociation constants (K D) of 47.0 nM for PSMA and 9.4 nM for CD3. It is used in the study of metastatic castration-resistant prostate cancer (mCRPC) [1] [2].
CAS Number:
[1442657-12-6]
Target:
Integrin
* VAT and and shipping costs not included. Errors and price changes excepted